MedPath

Prospective phase II study of tailored RadioTherapy according to the response after NeoAdjuvant Chemotherapy followed by surgery in patients with lymph node metastasis in axillary level II-III and/or internal mammary and/or supraclavicular lymph node at diagnosis.

Not Applicable
Recruiting
Conditions
Neoplasms
Registration Number
KCT0009061
Lead Sponsor
ational Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
424
Inclusion Criteria

1. Women aged 20-70
2. Patient must have pathologically diagnosed as invasive breast cancer
3. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
4. Patient must have clinically T1-4 breast cancer (before standard neoadjuvant chemotherapy±targeted therapy)
5. Patient must have lymph node metastasis in axillary level II-III and/or internal mammary and/or supraclavicular lymph node confirmed by fine needle aspirate(FNA) or imaging study (before standard neoadjuvant chemotherapy±targeted therapy)
6. Patient who have undergone breast conserving surgery or total mastectomy
7. Patient who have undergone sentinel lymph node biopsy, axillary lymph node sampling, or axillary lymph node dissection
8. Patients with hormone receptors, HER-2, Ki-67 index test results (HER-2 2+ cases require FISH or SISH)

Exclusion Criteria

1. In the case of distant metastasis (before standard neoadjuvant chemotherapy±targeted therapy)
2. Bilateral breast cancer patients
3. Male breast cancer patients
4. Patient with a history of radiation therapy to the ipsilateral breast or supraclavicular area in the past
5. Patient diagnosed with another cancer within 5years from the start date of radiation therapy(except for thyroid cancer, in situ cervical cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin)
6. If pregnant or breastfeeding
7. If standard neoadjuvant chemotherapy±targeted therapy has not been completed as planned
8. If there is no level II-III axillary lymph node involvement or supraclavicular lymph node metastasis, and only internal mammary lymph node metastasis is present at the time of diagnosis

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath